Published in Am J Transplant on June 09, 2016
Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant. Am J Transplant (2016) 0.76
Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice. Front Immunol (2017) 0.75
Graft Function and Intermediate-Term Outcomes of Kidney Transplants Improved in the Last Decade: Analysis of the United States Kidney Transplant Database. Transplant Direct (2017) 0.75
Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants. Front Med (Lausanne) (2017) 0.75
Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism. J Nephrol (2017) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
Kidney transplantation under FK 506. JAMA (1990) 7.45
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Immunosuppressive drugs for kidney transplantation. N Engl J Med (2004) 4.09
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43
Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation (2002) 3.42
Cyclosporine-associated chronic nephropathy. N Engl J Med (1984) 3.39
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 3.05
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet (2000) 2.81
Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol (2001) 2.80
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Expanded criteria donors for kidney transplantation. Am J Transplant (2003) 2.25
De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant (2009) 2.24
OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant (2014) 2.01
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90
Summary of the US FDA approval of belatacept. Am J Transplant (2012) 1.68
Kidney and pancreas transplantation in the United States, 1999-2008: the changing face of living donation. Am J Transplant (2010) 1.55
Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant (2007) 1.51
Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant (2002) 1.44
The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol (1993) 1.32
Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period. Lancet (1984) 1.31
Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med (1986) 1.29
Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol (2012) 1.21
Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant (2010) 1.20
Factors influencing long-term outcome after kidney transplantation. Transpl Int (2013) 1.14
Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation (2003) 1.14
Renal transplantation from extended criteria cadaveric donors: problems and perspectives overview. Transpl Int (2007) 1.13
Belatacept for kidney transplant recipients. Cochrane Database Syst Rev (2014) 0.99
CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A (2014) 0.98
Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant (2013) 0.93
Belatacept: from rational design to clinical application. Transpl Int (2011) 0.93
The predictive value of kidney allograft baseline biopsies for long-term graft survival. J Am Soc Nephrol (2013) 0.89
Optimal immunosuppression to prevent chronic allograft dysfunction. Kidney Int Suppl (2010) 0.83
Outcomes of transplantation using kidneys from donors meeting expanded criteria in Australia and New Zealand, 1991 to 2005. Transplantation (2009) 0.79
Kidney transplantation outcomes from expanded criteria donors, standard criteria donors or living donors older than 60 years. Ren Fail (2014) 0.79
Does belatacept improve outcomes for kidney transplant recipients? A systematic review. Transpl Int (2015) 0.78
Cardiovascular risk in recipients with kidney transplants from expanded criteria donors. Transplant Proc (2012) 0.78
Expanded criteria donors for kidney transplantation: quality control and results. Transplant Proc (2006) 0.78
Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk. Nefrologia (2012) 0.77
Lengthy cold ischemia time is a modifiable risk factor associated with low glomerular filtration rates in expanded criteria donor kidney transplant recipients. Transplant Proc (2009) 0.76
Long-term outcomes of kidney transplantation from expanded criteria deceased donors at a single center: comparison with standard criteria deceased donors. Transplant Proc (2014) 0.75
Renal transplantation in high-risk patients. Drugs (2007) 0.75